Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial

Thrombosis Research

Volumn 135, Issue 2, 2015, Pages 281-288

  Prins, Martin H ^a   Bamber, Luke ^b   Cano, Stefan J ^c   Wang, Maria Y ^d   Erkens, Petra ^a   Bauersachs, Rupert ^e   Lensing, Anthonie W A ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BAYER PHARMA AG   (Germany)

^c PENINSULA MEDICAL SCHOOL   (United Kingdom)

^d BAYER CORPORATION   (United States)

^e Max Ratschow Clinic for Angiology   (Germany)

Author keywords

Anti Clot treatment scale; Coagulation inhibitor; Pulmonary embolism; Rivaroxaban; Treatment satisfaction; Venous thrombosis

Indexed keywords

ANTIVITAMIN K; ENOXAPARIN; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; ANTI CLOT TREATMENT SCALE; ARTICLE; ASSESSMENT OF HUMANS; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NEOPLASM; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; CONTROLLED STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PATIENT SATISFACTION; PULMONARY EMBOLISM; THIOPHENES;

EID: 84921454374     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.11.008     Document Type: Article

References (42)

1. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-9.
2. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-60.
3. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-93.
4. Spencer FA, Emery C, Joffe SW, Pacifico L, Lessard D, Reed G, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis 2009;28:401-9.
5. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978-81.
6. Anderson Jr FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
7. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:122-30.
8. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton III LJ. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-8.
9. Pengo V, Lensing AWA, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64.
10. Prins MH, Lensing AWA, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013;11:21.
11. Cohen A, Martinez C, Wallenhorst C, Bamber L. Vitamin K antagonist treatment patterns and persistence after venous thromboembolism in non-cancer patients: VTE Epidemiology Group (VEG) Study. J Thromb Haemost 2013;11:27-8 [AS 17.2].
12. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419S-94S.
13. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart 2005;91:472-7.
14. Bristol-Myers Squibb. Coumadin Prescribing Information. Available at: http://packageinserts.bms.com/pi/pi-coumadin.pdf; 2011.
15. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239-45.
16. van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AWA. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. Curr Med Res Opin 2014;30:829-37.
17. Shahiwala A. Formulation approaches in enhancement of patient compliance to oral drug therapy. Expert Opin Drug Deliv 2011;8:1521-9.
18. Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf; 2009.
19. Bayer Pharma AG. Xarelto® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000944/WC500057108.pdf; 2014.
20. Bristol-Myers Squibb, Pfizer. Eliquis® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/002148/WC500107728.pdf; 2014.
21. Janssen Pharmaceuticals Inc. Xarelto® Prescribing Information. Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf; 2014.
22. Bristol-Myers Squibb Company. Pfizer Inc. Eliquis® Prescribing Information. Available at: http://packageinserts.bms.com/pi/pi-eliquis.pdf; 2014.
23. Boehringer Ingelheim International GmbH. Pradaxa® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-- -Product-Information/human/000829/WC500041059.pdf; 2014.
24. Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa® Prescribing Information. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf; 2014.
25. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013;369:1406-15.
26. Daiichi Sankyo Inc. Daiichi Sankyo receives approval for additional indications of LIXIANA® (edoxaban) in Japan. Available at: http://www.daiichisankyo.com/media-investors/media-relations/press-releases/detail/006189.html; 2014.
27. Konstantinides S, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galiè N, et al. ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014. http://dx.doi.org/10.1093/eurheartj/ehu283.
28. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.
29. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72.
30. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.
31. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.
32. Mueck W, Lensing AWA, Agnelli G, Décousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011;50:675-86.
33. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;51:549-61.
34. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.
35. Bamber L, Wang MY, Prins MH, Ciniglio C, Bauersachs R, Lensing AWA, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. Thromb Haemost 2013;110:732-41.
36. Cano SJ, Lamping DL, Bamber L, Smith S. The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients. Health Qual Life Outcomes 2012;10:120.
37. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 2005;8(Suppl. 1):S9-24.
38. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12.
39. Hochberg Y. A sharper Bonferroni procedure for multiple tests for significance. Biometrika 1988;75:800-2.
40. Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, Hoffman L, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004;26:1149-59.
41. Deitelzweig SB, Lin J, Kreilick C, Hussein M, Battleman D. Warfarin therapy in patients with venous thromboembolism: patterns of use and predictors of clinical outcomes. Adv Ther 2010;27:623-33.
42. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence, 6;2012. p.39-48.